Figlin Ra

14 papers receiving 238 citations

Peers

Figlin Ra
Comparison fields: 5 of 47
  • Oncology 101
  • Cancer Research 50
  • Immunology 67
  • Pulmonary and Respiratory Medicine 91
  • Molecular Biology 112
Replace M. Pfreundschuh with:
M. Pfreundschuh Germany
Chang Hun Lee South Korea
W. P. Peelen Netherlands
Ingirídur Skírnisdóttir Sweden
Marie Pierre Gaub France
Susanne Beck Germany
Siel Olbrecht Belgium
S. Mariucci Italy
Feiteng Lu China
Aurora Rizzo Italy
Figlin Ra relative to M. Pfreundschuh Germany M. Pfreundschuh's profile →
Citations per field
00.5×
M. Pfreundschuh · 1×
Citations per year

Countries citing papers authored by Figlin Ra

Since Specialization
Citations

This map shows the geographic impact of Figlin Ra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Figlin Ra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Figlin Ra more than expected).

Fields of papers citing papers by Figlin Ra

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Figlin Ra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Figlin Ra. The network helps show where Figlin Ra may publish in the future.

Co-authors

The 25 scholars most cited alongside Figlin Ra, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Figlin Ra Line = papers co-authored together Figlin Ra links everyone, so they are left out of the graph.

All Works

15 of 15 papers shown
#Work
1
Renal cell carcinoma: recent progress and future directions.
199786
2 198852
3
Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
200025
4
Phase I study of recombinant beta ser 17 interferon in the treatment of cancer.
198619
5
Alpha(human leukocyte)-interferon as treatment for non-small cell carcinoma of the lung: a phase II trial.
198317
6 201715
7
Biotherapy with interferon--1988.
198815
8
Technology evaluation: interleukin-2 gene therapy for the treatment of renal cell carcinoma.
19997
9
Biotherapy with interferon in solid tumors.
19873
10
Practice guidelines for pancreatic cancer.
20063
11 20102
12
Phase I study of Wellferon (human lymphoblastoid alpha-interferon) as cancer therapy: clinical results.
19832
13 20161
14 20021
15 20110

About Figlin Ra

Figlin Ra is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Radiology, Nuclear Medicine and Imaging and Surgery, having authored 15 papers that have together received 248 indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (5 papers), Cancer Immunotherapy and Biomarkers (3 papers), Lymphoma Diagnosis and Treatment (2 papers), Cancer Genomics and Diagnostics (2 papers), Renal and related cancers (2 papers), Chronic Lymphocytic Leukemia Research (2 papers), Bladder and Urothelial Cancer Treatments (2 papers) and CAR-T cell therapy research (2 papers). The work is most often cited by research in Oncology (101 citations), Cancer Research (50 citations), Immunology (67 citations), Pulmonary and Respiratory Medicine (91 citations) and Molecular Biology (112 citations). Figlin Ra has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Gregory Sarna, Arie S. Belldegrun, M. Linehan, David Parkinson, Robert H. Wiltrout, Walter E. DeWolf, Peter F.A. Mulders, Jean B. deKernion, Loretta M. Itri and Eliahu Mukamel. Their work appears in journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute, Annals of Oncology, Value in Health and Urologic Oncology Seminars and Original Investigations.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact